Literature DB >> 8900419

Cell kinetics and tumor regression during radiotherapy in head and neck squamous-cell carcinomas.

R Corvò1, W Giaretti, E Geido, G Sanguineti, R Orecchia, M Scala, G Garaventa, E Mora, V Vitale.   

Abstract

Head and neck squamous-cell carcinoma (HN-SCC) patient management is mainly based on TNM classification and needs be improved by considering other potentially useful prognostic factors. We examined the pre-radiotherapy tumor potential doubling time (Tpot) evaluated after in vivo infusion of bromodeoxyuridine and flow-cytometric analysis and the early clinical tumor regression after 40 Gy (40 Gy-TR). Tpot values and clinical 40 Gy-TR classes (minor and major) were available for 82 HN-SCC patients. Radiation therapy completion was done either with 1 dose per day (conventional regimen) or 2 doses per day (accelerated regimen). Local control was also available for follow-up times above 4 years. We found that major 40 Gy-TR was strongly correlated with fast tumor growth, characterized by Tpot values below 5 days, and that patients with major 40 Gy-TR showed better local control than those with minor 40 Gy-TR, independently from the radiotherapy regimen type. We also found that treatment completion with accelerated radiotherapy gave better local control for patients with major 40 Gy-TR and fast tumor growth than conventional radiotherapy. Multivariate analysis, performed on all patients, assigned an independent prognostic value to Tpot, tumor classification and 40 Gy-TR.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8900419     DOI: 10.1002/(SICI)1097-0215(19961009)68:2<151::AID-IJC1>3.0.CO;2-X

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  1 in total

1.  Hamming clustering techniques for the identification of prognostic indices in patients with advanced head and neck cancer treated with radiation therapy.

Authors:  G Paoli; M Muselli; R Bellazzi; R Corvó; D Liberati; F Foppiano
Journal:  Med Biol Eng Comput       Date:  2000-09       Impact factor: 2.602

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.